2023年度非小细胞肺癌放射治疗研究进展  

Advance in non-small cell lung cancer radiotherapy in 2023

作　　者：李加冉 袁双虎 Li Jiaran;Yuan Shuanghu(Department of Radiotherapy,Shandong Cancer Hospital Affiliated to Shandong First Medical University,Jinan 250117,China)

机构地区：[1]山东第一医科大学附属肿瘤医院放疗科,济南250117

出　　处：《肿瘤综合治疗电子杂志》2024年第1期38-43,共6页Journal of Multidisciplinary Cancer Management(Electronic Version)

基　　金：国家自然科学基金项目(NSFC82073345);山东省自然科学创新发展联合基金项目(ZR202209010002);济南市科技创新计划项目(202019060)。

摘　　要：肺癌是我国发病率和死亡率最高的恶性肿瘤,根据病理及细胞学肺癌可分为非小细胞肺癌(non-small cell lung cancer,NSCLC)及小细胞肺癌,其中NSCLC约占85%。晚期NSCLC患者预后差,放射治疗和化疗是主要的治疗手段,但随着放射治疗技术的创新和免疫治疗、靶向治疗的发展,在不同时期NSCLC的放射治疗模式逐渐呈现出新的格局。本文旨在介绍2023年度NSCLC放射治疗领域的研究进展。Lung cancer is the malignant tumor with the highest incidence of morbidity and mortality in China.According to pathology and cytology,lung cancer can be divided into non-small cell lung cancer(NSCLC)and small cell lung cancer,among which NSCLC accounts for about 85%.The prognosis of patients with advanced NSCLC disease is poor,and radiotherapy and chemotherapy are the main therapeutic methods.However,with the innovation of radiotherapy technology and the development of immunotherapy and targeted therapy,the radiotherapy mode of NSCLC gradually presents a new pattern in different periods.This paper aims to present the research progress in the field of radiotherapy in NSCLC in 2023.

关 键 词：非小细胞肺癌 放射治疗 免疫治疗 靶向治疗 

分 类 号：R734.2[医药卫生—肿瘤]